Using a GnRH Agonist to Treat Severe Polycystic Liver Disease in Women
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
This study is testing if a medication called leuprorelin can help reduce liver size in women with severe polycystic liver disease who are still experiencing growth despite other treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Sponsor | University Medical Center Groningen Academic / other |
| Locations | 2 sites (Nijmegen, Gelderland and 1 other locations) |
| Trial ID | NCT05478083 on ClinicalTrials.gov |
What this trial studies
This multicenter trial investigates the effects of the GnRH analogue leuprorelin on reducing liver volume in pre-menopausal women suffering from severe polycystic liver disease. Participants must have a significant liver size and ongoing growth despite existing therapies. The study aims to assess whether leuprorelin can effectively slow or halt the progression of liver enlargement, potentially delaying the need for liver transplantation.
Who should consider this trial
Good fit: Ideal candidates are pre-menopausal women aged 18 to 45 with a diagnosis of polycystic liver disease and significant liver enlargement.
Not a fit: Patients who do not have ongoing liver growth or those who are not using somatostatin analogues may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for women with severe polycystic liver disease, potentially reducing the need for liver transplantation.
How similar studies have performed: While there is existing evidence supporting the use of somatostatin analogues for polycystic liver disease, the use of GnRH agonists like leuprorelin in this context is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients * Diagnosis of polycystic liver disease defined as the presence of more than 10 liver cysts * Age between 18 to 45 (inclusive) years; * Very large liver for age, defined as the upper 10% of liver volumes in specific age categories (based on a retrospective polycystic liver disease registry, n=1.600 patients) * 18-30 yr; height adjusted TLV \> 2.0 L/m * 30-35 yr; height adjusted TLV \> 2.2 L/m * 35-40 yr; height adjusted TLV \> 2.5 L/m * 40-45 years; height adjusted TLV \> 3.0 L/m * Availability of at least 1 historical MRI or CT scan made between 5 to 1 years before baseline visit of this study * Ongoing liver growth, defined as an increase in absolute total liver volume between the historical MRI or CT scan and the MRI at screening of this trial * Since somatostatin analogues are proven efficacious therapy for polycystic liver disease at this time it is required that: * patients use a somatostatin analogue and still have confirmed liver growth; OR * patient have a specific reason not to use this medication, .e.g. patient used a somatostatin analogue in the past, but had to stop it due to inefficacy or because he/she did not tolerate it, patient has a contra-indication for using somatostatin analogues, no availability of somatostatin analogues * Voluntary written informed consent before performance of any study-related procedures not part of standard medical care, and able to read, comprehend, and respond to study questionnaires. Exclusion Criteria: Post-menopausal status or (vasomotor) symptoms indicating upcoming menopause * Anti Mullerian Hormone (AMH) measurement at screening visit \<0.03 ng/ml. * Active desire to have children, pregnancy or breast-feeding * Contra-indications for leuprorelin, such as history of cardiovascular disease, history of osteoporosis or osteoporosis determined by DEXA-scan at screening (T score ≤ - 2.5), or a known intolerance for leuprorelin * Liver transplantation or liver surgery expected within 1.5 years, to the discretion of the study doctor * Use of hormonal oral contra-conception containing estrogen and/or progesterone. In contrast, a hormone containing uterine device is not an exclusion criteria. * Contra-indications for MRI assessments (such as implants) or not able or willing to undergo MRI scan for other reasons (e.g. claustrophobia, profound obesity) * Kidney transplantation or chronic use of immunosuppressive agents (such as cyclosporine, mycophenolic acid, tacrolimus but not prednisolone) for other indications * Severe hypertension, defined as a systolic blood pressure \>160 mmHg and/or diastolic blood pressure \> 100 mm Hg. * Clinically significant, uncontrolled medical condition that, in the opinion of the investigator, would put the safety of the patient at risk through participation, or which would affect the efficacy of safety analysis if the condition exacerbated during the study, or that may significantly interfere with study compliance, such as, but not restricted to, recurrent cholangitis, recurrent ascites or hepato-venous outflow obstruction, (history of) depression * Participation in other interventional studies at the same time.
Where this trial is running
Nijmegen, Gelderland and 1 other locations
- Radboudumc — Nijmegen, Gelderland, Netherlands (Not_yet_recruiting)
- Groningen universitair medical center — Groningen, Netherlands (Recruiting)
Study contacts
- Study coordinator: Ron T Gansevoort
- Email: r.t.gansevoort@umcg.nl
- Phone: +31 50 3610923
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.